

**RETINA The Journal of Retinal and Vitreous Diseases**  
**Diagnostic and Therapeutic Challenges Section of Retina**  
 --Manuscript Draft--

<b>Manuscript Number:</b>	Retina-215-1330
<b>Full Title:</b>	Diagnostic and Therapeutic Challenges Section of Retina
<b>Article Type:</b>	Diagnostic & Therapeutic Challenges
<b>Keywords:</b>	Bear tracks, Congenital Hypertrophy of the Retinal Pigment Epithelium, CHRPE, Intraretinal RPE migration, Massive Reactive Gliosis, Multiples hamartomas, Unilateral RPE Dysgenesis
<b>Corresponding Author:</b>	SALVADOR PASTOR-IDOATE, MD, MSc Manchester Royal Eye Hospital-Manchester Vision Regeneration (MVR) Lab at NIHR/ Wellcome Trust Manchester, UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Manchester Royal Eye Hospital-Manchester Vision Regeneration (MVR) Lab at NIHR/ Wellcome Trust
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	SALVADOR PASTOR-IDOATE, MD, MSc
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	SALVADOR PASTOR-IDOATE, MD, MSc Heinrich Heimann, Professor Pearse A Keane, MD, PhD Konstantinos Balaskas, MD
<b>Order of Authors Secondary Information:</b>	
<b>Manuscript Region of Origin:</b>	UNITED KINGDOM
<b>Suggested Reviewers:</b>	Jose Carlos Pastor pastor@ioba.med.uva.es
<b>Opposed Reviewers:</b>	

January 30th, 2015

Dear Editors of Retina Journal

Please find enclosed our manuscript entitled: “**Diagnostic and Therapeutic Challenges**” that we would like to submit for consideration in the Diagnostic and Therapeutic Challenges section in Retina Journal.

After asking several experts for their opinion. This manuscript is presented for discussion of diagnosis. It was conducted to report unusual intra-retinal white-greyish lesions and multiple pigmented lesions mimicking “bear tracks” spreading throughout the superior hemi-retina, involving peripheral areas, posterior pole and macular area. The features of these lesions were described with an Optical Coherence Tomography imaging technology, Wide Field colour and Fundus Autofluorescence. We also provide some differential diagnoses for discussion.

We hope that the style and contents of our article are in agreement with the requirements of the Journal but please do not hesitate to contact us should the need arise.

Yours sincerely,

Salvador Pastor-Idoate

Clinical Research Fellow in medical Retina

Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WL, UK

E-mail: [pastor.idoate@gmail.com](mailto:pastor.idoate@gmail.com)

Telephone: +44 07448823127

## Diagnostic and Therapeutic Challenges

Salvador. Pastor-Idoate, MD 1,2, Heinrich. Heimann, Professor, MD, PhD3, Pearse. Keane, MD, PhD4,  
Konstantinos. Balaskas, MD1

1Manchester Royal Eye Hospital

2Manchester Vision Regeneration (MVR) Lab at NIHR/ Wellcome Trust

Manchester CRF, UK

3Royal Liverpool and Broadgreen University Hospitals NHS Trust

4Moorfields Eye Hospital

\*Corresponding author contact information:

Salvador Pastor-Idoate

Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WL, UK

E-mail: [pastor.idoate@gmail.com](mailto:pastor.idoate@gmail.com)

Telephone: +4407448823127

Fax number: +441612765642

1  
2  
3  
4  
5  
6 This case is submitted by Drs. Salvador Pastor-Idoate<sup>1,2</sup>, Heinrich Heimann<sup>3</sup>, Pearse A.  
7  
8 Keane<sup>4</sup>, and Konstantinos Balaskas<sup>1</sup>; commented by Dr. Brandon J. Lujan.  
9

10  
11 <sup>1</sup>Manchester Royal Eye Hospital

12  
13  
14 <sup>2</sup>Manchester Vision Regeneration (MVR) Lab at NIHR/ Wellcome Trust  
15  
16 Manchester CRF, UK

17  
18  
19 <sup>3</sup>Royal Liverpool and Broadgreen University Hospitals NHS Trust

20  
21 <sup>4</sup>Moorfields Eye Hospital  
22  
23  
24

## 25 **Case Report**

26  
27 A 29-year-old woman was referred to our center in November 2014, after a  
28  
29 routine examination in her local optician, to assess multiples naevi in the periphery of  
30  
31 the fundus. These areas of pigment have not been described to the patient in the past.  
32  
33 The patient had no ocular complaints and no previous medical history, ocular history or  
34  
35 systemic treatments. She had no family history of visual problems, was born of non-  
36  
37 consanguineous parents, and was otherwise well. The best corrected visual acuity was  
38  
39 20/20 in the right eye (RE) and 20/25 in the left eye (LE). The entire examination was  
40  
41 normal except for the retina in the left eye.  
42  
43  
44  
45

46  
47 Examination in the LE showed unusual intra-retinal white-greyish lesions and  
48  
49 multiple pigmented lesions mimicking “bear tracks” spreading throughout the superior  
50  
51 hemi-retina, involving peripheral areas, posterior pole and macular area. The inferior  
52  
53 retina looked unremarkable. The fundus appearance of the RE was completely normal.  
54  
55

56  
57 A detailed vitreoretinal examination was performed along with spectral domain  
58  
59 (Spectralis®) optical coherence tomography (OCT) (Figure 1A and 1B) and Wide Field  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 color (Figure 2A, 2B, 3C) and Fundus Autofluorescence (WF-FAF) (Optos PLC,  
7  
8 Dunfermline, Scotland) (Figure 3A and 3B). OCT scans taken at the level of the  
9  
10 unusual white-greyish lesions and pigmented lesions in the LE showed two types of  
11  
12 lesion patterns. Mild-reflective masses in the inner plexiform layer with slightly optical  
13  
14 shadowing posterior to the lesion and hyper-reflective patches in the RPE-Bruch's  
15  
16 complex layer without optical shadowing posterior to the lesion, respectively. Fundus  
17  
18 Autofluorescence (FAF) just showed hypo-fluorescent round structures, corresponding  
19  
20 with the hyper-reflective patches in the OCT scans. The patient was observed without  
21  
22 any intervention.  
23  
24  
25  
26

27  
28 Three weeks later the ophthalmic examination was unchanged. The patient was  
29  
30 observed without any change in her symptoms. No further investigations were made  
31  
32 because of lack of evidence of an inflammatory cause.  
33  
34

35  
36 We believe that the pigmented lesions present in the LE represent Grouped  
37  
38 Congenital Hypertrophy of the Retinal Pigment Epithelium (Grouped CHRPE). Indeed  
39  
40 they present with a typical configuration of larger lesions in the peripheral retina  
41  
42 becoming smaller with increased proximity to the optic disc. The unilateral presentation  
43  
44 in the absence of family history or gastro-intestinal symptoms would not warrant further  
45  
46 investigation to exclude familial polyposis in this case. The associated unusual intra-  
47  
48 retinal white-greyish lesions were rather more puzzling. Our differential diagnoses for  
49  
50 such lesions include the following ones:  
51  
52

- 53  
54 1. Multiples hamartomas of the retina<sup>1-2</sup>
  - 55  
56 2. Intraretinal RPE migration into the neurosensory retina<sup>3</sup>
  - 57  
58 3. Unilat RPE Dysgenesis<sup>4-5</sup>
- 59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 4. Massive Reactive Gliosis<sup>6-7</sup>  
7

8           What are these lesions in the inner plexiform layer in the OCT scans?  
9

10 **References**  
11

- 12  
13 1. Schachat AP, Shields JA, Fine SL, et al. Combined hamartoma of the retina and  
14  
15 retinal pigment epithelium. *Ophthalmology* 1984;91:1609-1615.  
16  
17  
18 2. Huot CS, Desai KB, Shah VA. Spectral domain optical coherence tomography of  
19  
20 combined hamartoma of the retina and retinal pigment epithelium. *Ophthalmic Surg*  
21  
22 *Lasers Imaging* 2009;40:322-324.  
23  
24  
25 3. Schneider, S. and Green, W.R. Congenital and acquired lesions of the retinal  
26  
27 pigment epithelium. in: G. Coscas, F. Cardillo Piccolino (Eds.) *Retinal Pigment*  
28  
29 *Epithelium and Macular Diseases*. Kluwer, Dordrecht, The Netherlands; 1998:69–80  
30  
31 (Doc Ophthalmol Proc Ser. vol 62)  
32  
33  
34  
35 4. Renz J, Fein JG, Vora R, et al . Unilateral retinal pigment epithelium dysgenesis may  
36  
37 be a bilateral disease. *Arch Ophthalmol* 2012;130:1340-1342.  
38  
39  
40 5. Cohen SY, Fung AE, Tadayoni R, et al. Unilateral retinal pigment epithelium  
41  
42 dysgenesis. *Am J Ophthalmol* 2009;148:914-919.e2.  
43  
44  
45 6. Bal N, Doran F, Ergin M, et al. Massive retinal gliosis: A case report and literature  
46  
47 review. *Aegean Pathol J* 2005;2:45-48.  
48  
49  
50 7. Sahel JA, Frederick AR Jr, Pesavento R, et al. Idiopathic retinal gliosis mimicking a  
51  
52 choroidal melanoma. *Retina* 1988;8:282-287.  
53  
54  
55

56 **Commentary**  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 **Dr. Brandon J. Lujan (San Francisco, California):** Salvador and co-authors present a  
7  
8 diagnostic challenge of an asymptomatic 30 year-old woman with intra-retinal whitish  
9  
10 lesions. No past medical history or extra-ophthalmic exam findings are given, but the  
11  
12 lesions have been evaluated by multimodal imaging and a differential can be formed  
13  
14 primarily from the optical coherence tomography (OCT) studies.  
15  
16

17  
18 The highest resolution OCT image of the retinal lesions in question is found in  
19  
20 Figure 2, which demonstrates a hyper-reflective, smooth, round intrinsic lesion that  
21  
22 appears to be centered at the junction of the inner nuclear layer (INL) and inner  
23  
24 plexiform layer (IPL). There is some heterogeneity within the lesion such that there is  
25  
26 more hyper-reflectivity at its inner boundary. This lesion appears associated with the  
27  
28 OCT signature of superficial retinal vasculature, discreet focal hyper-reflectivity with  
29  
30 distal attenuation or “shadowing”. There is a mass effect on the inner retinal layers with  
31  
32 inward displacement of the moderately thinned IPL, ganglion cell and nerve fiber layers.  
33  
34 There is a similar mass effect on the outer retina with outward displacement of the INL,  
35  
36 synaptic outer plexiform layer (OPL), Henle fiber layer (HFL), and outer nuclear layer  
37  
38 (ONL). There is the suggestion of compression of the ONL deep to the lesion, though  
39  
40 without being able to visualize the ONL/HFL boundary clearly this cannot be confirmed.  
41  
42 The external limiting membrane is continuous, but bowed outward. The reflectivity of  
43  
44 the ellipsoid zone is attenuated and the interdigitation zone (IZ) is not visible distal to the  
45  
46 lesion. While the photoreceptor inner-segment thickness length appears essentially  
47  
48 normal, there is a clear decrease of the photoreceptor outer-segment lengths compared  
49  
50 to the surrounding retina, consistent with the focal loss of the IZ band. The retinal  
51  
52 pigment epithelium and choroid appear intact and unremarkable.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 There is a smaller lesion additionally identified in Figure 2 which is obscured in  
7  
8 the figure by a white asterisk that the authors have indicated represents a retinal vessel.  
9  
10 However, the presence of vasculature within the substance of the inner nuclear layer  
11  
12 would be abnormal, and is likely not the case here. If this additional lesion were due to  
13  
14 vasculature present in the INL/IPL interface, then this would be abnormally large for the  
15  
16 superficial capillary plexus that resides there, and would be expected to demonstrate  
17  
18 distal signal attenuation. Consequently, this smaller lesion likely represents another  
19  
20 instance of the larger pathology found at the INL/IPL interface nasal to it.  
21  
22  
23  
24

25 Figure 3 shows the extent of the multiple foci of the lesions, and their consistent  
26  
27 layers of origin and mass effect on the surrounding retina. Additionally, there are some  
28  
29 slivers of hypo-reflectivity that appear within these hyper-reflective lesions. This figure  
30  
31 also demonstrates the second pathologic feature of this case, congenital hypertrophy of  
32  
33 the retinal pigment epithelium (CHRPE), which is seen as increased RPE hyper-  
34  
35 reflectivity and distal choroidal attenuation. Some of the distinct hyper-reflective lesions  
36  
37 have CHRPE deep to them, yet some do not. Additionally, some CHRPE exists away  
38  
39 from the retinal lesions, making the relationship between these lesions unclear. No  
40  
41 volumetric comparison of these features is presented to fully evaluate.  
42  
43  
44  
45  
46

47 There are several diagnostic categories that should be considered based on the  
48  
49 intraretinal OCT appearance of the hyper-reflective lesions. These can be broken down  
50  
51 into ischemic conditions, inflammatory or infectious sequelae, neoplasm, or non-  
52  
53 neoplastic malformations.  
54  
55

56 Vascular events include cotton wool spots (CWS) stemming from ischemia or  
57  
58 infarction of the nerve fiber layer, and paracentral acute middle maculopathy (PAMM)  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6 secondary to deep capillary ischemia. CWS can appear as globular hyper-reflective  
7  
8 masses, and can be seen to have a mass effect on the surrounding retina, and can  
9  
10 even impinge on the photoreceptor layers .<sup>1</sup> However, they are centered and appear to  
11  
12 emanate from the nerve fiber layer, unlike this case where there is a relatively normal  
13  
14 ganglion cell layer and nerve fiber layer overlying it. PAMM lesions do involve the INL  
15  
16 predominantly and can cause hyper-reflectivity of it as well as the IPL. <sup>2</sup> While PAMM  
17  
18 can cause some thickening of these retinal layers due to cell body swelling, this is  
19  
20 generally quite limited and wouldn't cause the massive appearance of these lesions  
21  
22 present in this case. Most importantly, CWS and PAMM have a relatively brief life cycle  
23  
24 and would be expected to change somewhat over the 3-week time period slightly, and  
25  
26 eventually cause local retinal layer thinning. The authors have indicated that these  
27  
28 lesions remained unchanged, so ischemia can be excluded from consideration.  
29  
30  
31  
32  
33  
34

35 Infectious etiologies such as those due to *Toxoplasmosis gondii* in posterior outer  
36  
37 retinal toxoplasmosis should be considered and have been associated with globular  
38  
39 lesions affecting the inner retina representing areas of focal retinitis.<sup>3</sup> However, the  
40  
41 absence of involvement of the outer retinal, chorioretinal scars, vitritis, or associated  
42  
43 symptomatology indicates that this diagnosis can be eliminated.  
44  
45  
46

47 The authors suggest several possible diagnoses including intraretinal RPE  
48  
49 migration, unilateral RPE dysgenesis, massive retinal gliosis, and multiple hamartomas  
50  
51 of the retina.  
52  
53

54 RPE migration into the neurosensory retina should not be considered for a  
55  
56 variety of reasons. Initially, there is no significant distal signal attenuation from these  
57  
58 lesions. Secondly, there is a uniformity and smoothness of these retinal lesions that  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 would not be expected in RPE migration, where variability of the signal and a more  
7  
8 punctate appearance is expected. Finally, true RPE migration is rarely imaged internal  
9  
10 to the HFL.  
11

12  
13 Unilateral RPE dysgenesis (URPED) can similarly be excluded as it is  
14  
15 characterized by contiguous RPE changes with a circumpapillary scalloped border that  
16  
17 would have been apparent on FAF imaging, and would demonstrates dramatic outer  
18  
19 retinal and RPE loss on OCT. Massive retinal gliosis has been diagnosed in patients  
20  
21 with NLP eyes undergoing enucleation specimens and this diagnosis would not apply to  
22  
23 an asymptomatic patient with multiple lesions much smaller than a millimeter in  
24  
25 diameter.  
26  
27  
28  
29

30 While the authors suggest the broad diagnostic category of multiple hamartomas  
31  
32 of the retina, they only reference papers suggesting combined hamartoma of the retina  
33  
34 and the retinal pigment epithelium. Because combined hamartoma can contain features  
35  
36 of retinal and RPE involvement, the diagnosis is tempting to consider in this case where  
37  
38 there is both retinal and underlying RPE hyperpigmentation. However, while fluorescein  
39  
40 angiography was not presented, the OCT appearance does not suggest that there are  
41  
42 significant vascular changes characteristic of combined hamartomas. Additionally, the  
43  
44 multifocal nature of the retinal lesions presented in this case, the absence of overlying  
45  
46 epiretinal membrane, or retinal disorganization make this diagnosis untenable.  
47  
48 However, other types of multiple hamartomas must be considered, and are ultimately  
49  
50 the most likely diagnosis in this patient.  
51  
52  
53  
54  
55

56 Retinal astrocytic hamartomas are benign, vascularized glial tumors of the retina  
57  
58 that may be acquired and congenital and have been described in by Stratus OCT.<sup>4</sup> In  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 this series of 15 cases there was a subtype of lesions that is not contiguous with the  
7  
8 optic nerve and consisted of a smooth hyper-reflective mass that appeared to emanate  
9  
10 from the inner retina. Further, this did not contain internal cystic spaces, nor was it  
11  
12 associated with exudation. While the lesion of this subtype shown as the example  
13  
14 showed signal loss deep to the lesion, it is likely that this was due to limitations of time-  
15  
16 domain OCT without the benefits of broader bandwidth light sources, better detectors  
17  
18 and frame-averaging. This subtype of astrocytic hamartoma is most consistent with the  
19  
20 findings presented in this Diagnostic Challenge.  
21  
22  
23  
24

25 The pathology of astrocytic hamartomas has been depicted, first by McLean et  
26  
27 al, where the appearance of origination in the INL/IPL interface<sup>5</sup> mirrors that of the  
28  
29 SDOCTs in the present case. While pathology was obtained from a larger lesion than  
30  
31 what is presented here, it is interesting to note that there were some internal vascular  
32  
33 changes and a loss of the photoreceptor inner and outer segments apparent  
34  
35 immediately below the lesion.  
36  
37  
38  
39

40 One final possibility that must be considered in this case is spontaneously  
41  
42 regressed retinoblastomas, or retinocytomas. These are tumors of undifferentiated  
43  
44 retinal precursor cell lines that have been reported at the junction of the INL and IPL  
45  
46 and resemble the whitish translucent lesions found in this case.<sup>6</sup> However this  
47  
48 diagnosis is extremely unlikely given that each of the nodules in this case are at  
49  
50 essentially the same state of progression and relatively the same size. Furthermore,  
51  
52 there is any evidence of calcification or pattern of pigment change to suggest prior  
53  
54 neoplastic lesions.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 CHRPE exists unilaterally in this patient in an unmistakable “bear tracks” pattern,  
7  
8 and is not in itself a diagnostic challenge. Given that there is not exact spatial co-  
9  
10 localization it is difficult to state with confidence that there is a relationship between  
11  
12 these hamartomas and the CHRPE. If each hamartoma had underlying CHRPE and  
13  
14 each CHRPE had overlying hamartoma it would be highly suggested that they are  
15  
16 correlated. Given that CHRPE is such a common finding it is more likely that these are  
17  
18 independent processes rather than there being a causal relationship, however further  
19  
20 genetic analysis may demonstrate otherwise.  
21  
22  
23

24  
25 The likely diagnosis of this case is multiple astrocytic hamartomas and congenital  
26  
27 hypertrophy of the retinal pigment epithelium (CHRPE). Multiple astrocytic hamartomas  
28  
29 have been previously described, almost exclusively in the context of the tuberous  
30  
31 sclerosis complex (TSC). The presentation of this syndrome can be subclinical and  
32  
33 may originate after fundusoscopic examination. The possibility of TSC should be further  
34  
35 evaluated by dermatological and neurological examination in addition to neuroimaging  
36  
37 and genetic analysis<sup>7</sup> before a definitive diagnosis can be made.  
38  
39  
40  
41

## 42 **References**

- 43  
44 1. Lujan BJ, Coady PA, McDonald HR. Spectral domain optical coherence tomography  
45  
46 imaging of Purtscher-like retinopathy. Retin Cases Brief Rep. 2014;8:283-285.  
47  
48
- 49 2. Rahimy E, Sarraf D. Paracentral acute middle maculopathy spectral-domain optical  
50  
51 coherence tomography feature of deep capillary ischemia. Curr Opin Ophthalmol,  
52  
53 2014;25:207-212.  
54  
55
- 56 3. Lujan BJ. Spectral domain optical coherence tomography imaging of punctate outer  
57  
58 retinal toxoplasmosis. Saudi J Ophthalmol 2014;28:152-156.  
59  
60  
61  
62  
63  
64  
65

4. Shields CL, Benevides R, Materin MA, Shields JA. Optical coherence tomography of retinal astrocytic hamartoma in 15 cases. *Ophthalmology* 2006;113:1553-1557.
5. McLean JM. Astrocytoma (True Glioma) of the Retina. *Arch Ophthalmology* 1937.
6. Saktanasate J, Vongkulsiri S, Khoo CT. Invisible Retinoblastoma. *JAMA Ophthalmol* 2015;133:e151123.
7. Roach ES, Sparangana SP. Diagnosis of tuberous sclerosis complex. *J Child Neural*. 2004;19:643-649.

**Editor's Note:** Drs. Pastore-Ildoate, Heimann, Keane, and Balaskas have presented a 29-year-old woman with multiple peripheral pigmented lesions in her left eye. The presenters feel that the pigmented lesions represent Grouped Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE) and give a differential diagnosis for the puzzling grayish-white intraretinal lesions.

- I. Multiple hamartomas of the retinal detachment
- II. Intraretinal RPE migration
- III. URPED
- IV. Massive reactive gliosis

They ask for clarification concerning the lesion in the inner plexiform layer on their SB-OCT studies.

Dr. Brandon Lujan consults for us on this case and makes a detailed analysis of the lesion in question. Based on the OCT findings, he adds to the differential diagnosis of these lesions.

- I. Ischemia

- 1
- 2
- 3
- 4
- 5
- 6 A. Cotton-wool spots
- 7
- 8 B. Paracentral Acute Middle Maculopathy
- 9
- 10 II. Inflammatory/Infectious
- 11
- 12 A. Toxoplasmosis (outer retinal)
- 13
- 14
- 15 III. Tumor
- 16
- 17 A. Retinal astrocytic hamartoma
- 18
- 19 B. Retinocytoma
- 20
- 21
- 22

23 He then reviews the differential diagnosis provided by the presenters. He  
24 discards the notion of RPE migration, URPED, and combined retinal-RPE hamartomas.  
25 He offers retinal astrocytic hamartoma as a diagnostic possibility. He references  
26 Shields paper, noting that there was a subgroup in that series where the lesions were  
27 not contiguous with the optic nerve and consisted of a smooth hyper-reflective mass  
28 that emanated from the inner retina. He feels that this subtype of astrocytic hamartoma  
29 is most consistent with the case presented in this challenge. He discusses and  
30 eliminates another whitish tumor reported at the junction of the INL and IPL,  
31 retinocytomas.  
32

33 Dr. Brandon Lujan concludes his analysis of this case by noting the relationship  
34 between multiple astrocytic hamartomas and tuberous sclerosis. He recommends  
35 further evaluation by dermatological and neurological specialists, neuroimaging, and  
36 genetic analysis.  
37

38 We thank Drs. Pastore-Indoate, Heimann, Keane, and Balaskas for their case,  
39 and Dr. Brandon Lujan for his consultation.  
40

## 41 **Figures**

42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6 Figure 1. Optical coherence tomography scans at presentation.

7  
8 A-I. Horizontal OCT line scan through the fovea of the RE.

9  
10 A-II. Horizontal OCT line scan through the fovea of the LE showing small  
11 mild-reflective lesions at inner plexiform layer.  
12  
13  
14

15 Figure 2.

16  
17 A-I. Horizontal OCT line scan of the LE through the white greyish lesion  
18 (yellow arrow).  
19  
20  
21

22 A-II. Magnification of the horizontal OCT line scan showing a mild-reflective  
23 mass in the inner plexiform layer with slightly optical shadowing posterior  
24 to the lesion at inner plexiform layer (yellow asterisk). White asterisk  
25 corresponds with the retinal vessel.  
26  
27  
28  
29  
30  
31

32 Figure 3.

33  
34 A-I. Horizontal OCT line scan of the LE through the superior vascular arcade  
35 crossing the two types of lesions.  
36  
37  
38

39 A-II. Color fundus photograph of the LE revealing the unusual intra-retinal  
40 white-greyish lesions and multiple pigmented lesions. The white-greyish  
41 lesions and the pigmented lesions in the color fundus picture correspond  
42 with the black and white lesions respectively in the grayscale of the OCT.  
43  
44  
45  
46  
47  
48

49 A-III. Horizontal OCT line scan showing two types of lesion patterns. Mild-  
50 reflective masses in the inner plexiform layer with slightly optical  
51 shadowing posterior to the lesion (yellow asterisks) and hyper-reflective  
52 patches in the RPE-Bruch's complex layer without optical shadowing  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

posterior to the lesion, respectively (purple asterisks). White asterisks correspond with the retinal vessels.

Figure 4.

- A-I. Color fundus photograph of the LE showing the lesions spreading throughout the superior hemi-retina, involving peripheral areas, posterior pole and macular area.
- A-II. Color fundus photograph of the RE.
- A-III. Color fundus photograph of the LE showing the inferior hemi-retina, apparently normal.

Figure 5.

- A-I. Fundus autofluorescence photograph of the RE.
- A-II. Fundus autofluorescence photograph of the LE showing hypo-fluorescent round structures, corresponding with the hyper-reflective patches in the OCT scans.



Figure 1

[Click here to download Figure \(Please type in the figure number in the Description Box; Fig 1, Fig 2, etc.\)](#) FIGURE 1.jpg



Figure 2

[Click here to download Figure \(Please type in the figure number in the Description Box; Fig 1, Fig 2, etc.\) figure 2.jpg](#)








Figure 3

[Click here to download Figure \(Please type in the figure number in the Description Box; Fig 1, Fig 2, etc.\) figure 3.jpg](#)










[Click here to access/download](#)


**Copyright Form (No longer Necessary) New Process**  
2151330 lauren.hall CTA and ACF.pdf






[Click here to access/download](#)


**Copyright Form (No longer Necessary) New Process**  
2151330 RETINA CTA Pastor.pdf






[Click here to access/download](#)

**Copyright Form (No longer Necessary) New Process**  
2151330 RETINA CTA-PEARSE.pdf








[Click here to access/download](#)

**Copyright Form (No longer Necessary) New Process  
2151330 Heiman.pdf**



## RETINA Author Declaration Form

### Statement of Authorship

Thank you for your submission to RETINA. The Journal now adheres to guidelines regarding transparency of authorship as outlined in the Uniform Requirements produced by the International Committee of Medical Journal Editors (<http://www.icmje.org/>).

This form must be completed by each author. It is the responsibility of the corresponding author, prior to submitting the manuscript, to confirm that each coauthor meets the requirements for authorship, and to collect the forms and upload them if/when the manuscript receives a decision that invites a revision (these forms are not required at submission). All those designated as authors must meet all four criteria listed below. Individuals who do not meet these criteria must be listed in the Acknowledgments.

1. Substantial contributions to conception and design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Manuscript Title:** \_\_\_\_\_

**Diagnostic and Therapeutic Challenges Section of Retina**

**Manuscript Number (if known):** MS-215-1330

Indicate your contributions to the Work by checking the applicable boxes. Note that you must meet the four criteria to qualify for authorship.

**1. (Check at least 1 of the boxes below to be considered an author)**

- Conception and design of the work/project
- Acquisition of data
- Conceptualization of the manuscript and review and synthesis of the literature
- Analysis and interpretation of data

**2. (Check at least 1 of the boxes below to be considered an author)**

- Drafting of the manuscript
- Critical review and revision of the manuscript

**3. (Must be checked to be considered an author)**

- Final approval of the version to be published

**4. (Must be checked to be considered an author)**

- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

### Author Guarantee Statement

By signing this form you guarantee that:

- 1) The manuscript contains original material that will not be submitted elsewhere concurrently

- 2) All authors have contributed to the work and are familiar with the primary data; each has read the final manuscript, and approved its contents
- 3) All authors have agreed to have their name added to the paper
- 4) All persons who have made substantial contributions to the work reported in this manuscript are included as authors, or are acknowledged (this includes anyone who may have been paid to draft or revise the paper).
- 5) The manuscript is free of falsification, fabrication, plagiarism and self-plagiarism. All applicable principles of scientific integrity, including ethical treatment of human subjects and humane treatment of animals, have been followed. In signing this form you testify that an appropriate institutional or public board approved the protocols for human or animal subject use
- 6) All funding sources that supported the work are acknowledged. Any potential conflicts of interest on the part of any authors have been supplied as part of the submission process. By signing this form you agree you will examine typeset proofs as supplied by the publisher prior to publication to ensure all relevant financial disclosures and other potential conflicts of interest have been accurately included within the manuscript

**Indemnification Statement**

By signing this form you agree to indemnify RETINA and the Publisher and hold it harmless from all damages and all reasonable expenditures incurred by the Journal/Publisher as the result of any charge or claim of copyright infringement or violation of proprietary rights asserted against the Journal/Publisher by third parties as a result of the Journal/Publisher use and publication of the manuscript

**Author acting as guarantor:**

Name (PLEASE PRINT):

Heinrich Heimann

---

Signature:



---

Date (month/day/year): 05/17/2015

**PLEASE UPLOAD THIS FORM WHEN YOU SUBMIT YOUR REVISED MANUSCRIPT AT <http://www.editorialmanager.com/retina/> OR EMAIL TO [retina@retinajournal.com](mailto:retina@retinajournal.com).**

## RETINA Author Declaration Form

### Statement of Authorship

Thank you for your submission to RETINA. The Journal now adheres to guidelines regarding transparency of authorship as outlined in the Uniform Requirements produced by the International Committee of Medical Journal Editors (<http://www.icmje.org/>).

This form must be completed by each author. It is the responsibility of the corresponding author, prior to submitting the manuscript, to confirm that each coauthor meets the requirements for authorship, and to collect the forms and upload them if/when the manuscript receives a decision that invites a revision (these forms are not required at submission). All those designated as authors must meet all four criteria listed below. Individuals who do not meet these criteria must be listed in the Acknowledgments.

1. Substantial contributions to conception and design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Manuscript Title: Diagnostic and Therapeutic Challenges  
Section of Retina

Manuscript Number (if known): 215-1330

Indicate your contributions to the Work by checking the applicable boxes. Note that you must meet the four criteria to qualify for authorship.

**1. (Check at least 1 of the boxes below to be considered an author)**

- Conception and design of the work/project  
 Acquisition of data  
 Conceptualization of the manuscript and review and synthesis of the literature  
 Analysis and interpretation of data

**2. (Check at least 1 of the boxes below to be considered an author)**

- Drafting of the manuscript  
 Critical review and revision of the manuscript

**3. (Must be checked to be considered an author)**

- Final approval of the version to be published

**4. (Must be checked to be considered an author)**

- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

### Author Guarantee Statement

By signing this form you guarantee that:

- 1) The manuscript contains original material that will not be submitted elsewhere concurrently

- 2) All authors have contributed to the work and are familiar with the primary data; each has read the final manuscript, and approved its contents
- 3) All authors have agreed to have their name added to the paper
- 4) All persons who have made substantial contributions to the work reported in this manuscript are included as authors, or are acknowledged (this includes anyone who may have been paid to draft or revise the paper).
- 5) The manuscript is free of falsification, fabrication, plagiarism and self-plagiarism. All applicable principles of scientific integrity, including ethical treatment of human subjects and humane treatment of animals, have been followed. In signing this form you testify that an appropriate institutional or public board approved the protocols for human or animal subject use
- 6) All funding sources that supported the work are acknowledged. Any potential conflicts of interest on the part of any authors have been supplied as part of the submission process. By signing this form you agree you will examine typeset proofs as supplied by the publisher prior to publication to ensure all relevant financial disclosures and other potential conflicts of interest have been accurately included within the manuscript

**Indemnification Statement**


By signing this form you agree to indemnify RETINA and the Publisher and hold it harmless from all damages and all reasonable expenditures incurred by the Journal/Publisher as the result of any charge or claim of copyright infringement or violation of proprietary rights asserted against the Journal/Publisher by third parties as a result of the Journal/Publisher use and publication of the manuscript

**Author acting as guarantor:**

Name (PLEASE PRINT):

PEARSE KENNEDY

Signature:



Date (month/day/year):

28/5/15

**PLEASE UPLOAD THIS FORM WHEN YOU SUBMIT YOUR REVISED MANUSCRIPT AT <http://www.editorialmanager.com/retina/> OR EMAIL TO [retina@retinajournal.com](mailto:retina@retinajournal.com).**

## RETINA Author Declaration Form

### Statement of Authorship

Thank you for your submission to RETINA. The Journal now adheres to guidelines regarding transparency of authorship as outlined in the Uniform Requirements produced by the by the International Committee of Medical Journal Editors (<http://www.icmje.org/>).

This form must be completed by each author. It is the responsibility of the corresponding author, prior to submitting the manuscript, to confirm that each coauthor meets the requirements for authorship, and to collect the forms and uploaded them if/when the manuscript receives a decision that invites a revision (these forms are not required at submission). All those designated as authors must meet all four criteria listed below. Individuals who do not meet these criteria must be listed in the Acknowledgments.

1. Substantial contributions to conception and design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Manuscript Title:** Diagnostic and therapeutic challenges  
section of Retina

**Manuscript Number (if known):** RETINA - 2 - 15 - 1330

Indicate your contributions to the Work by checking the applicable boxes. Note that you must meet the four criteria to qualify for authorship.

**1. (Check at least 1 of the boxes below to be considered an author)**

- Conception and design of the work/project
- Acquisition of data
- Conceptualization of the manuscript and review and synthesis of the literature
- Analysis and interpretation of data

**2. (Check at least 1 of the boxes below to be considered an author)**

- Drafting of the manuscript
- Critical review and revision of the manuscript

**3. (Must be checked to be considered an author)**

- Final approval of the version to be published

**4. (Must be checked to be considered an author)**

- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

### Author Guarantee Statement

By signing this form you guarantee that:

- 1) The manuscript contains original material that will not be submitted elsewhere concurrently


- 2) All authors have contributed to the work and are familiar with the primary data; each has read the final manuscript, and approved its contents
- 3) All authors have agreed to have their name added to the paper
- 4) All persons who have made substantial contributions to the work reported in this manuscript are included as authors, or are acknowledged (this includes anyone who may have been paid to draft or revise the paper).
- 5) The manuscript is free of falsification, fabrication, plagiarism and self-plagiarism. All applicable principles of scientific integrity, including ethical treatment of human subjects and humane treatment of animals, have been followed. In signing this form you testify that an appropriate institutional or public board approved the protocols for human or animal subject use
- 6) All funding sources that supported the work are acknowledged. Any potential conflicts of interest on the part of any authors have been supplied as part of the submission process. By signing this form you agree you will examine typeset proofs as supplied by the publisher prior to publication to ensure all relevant financial disclosures and other potential conflicts of interest have been accurately included within the manuscript

**Indemnification Statement**

By signing this form you agree to indemnify RETINA and the Publisher and hold it harmless from all damages and all reasonable expenditures incurred by the Journal/Publisher as the result of any charge or claim of copyright infringement or violation of proprietary rights asserted against the Journal/Publisher by third parties as a result of the Journal/Publisher use and publication of the manuscript

**Author acting as guarantor:**

Name (PLEASE PRINT): SALVADOR PASTEN IBOATE

Signature: 

Date (month/day/year): 28/5/15

**PLEASE UPLOAD THIS FORM WHEN YOU SUBMIT YOUR REVISED MANUSCRIPT AT <http://www.editorialmanager.com/retina/> OR EMAIL TO [retina@retinajournal.com](mailto:retina@retinajournal.com).**